Cho J, Noonan SH, Fay R, Apovian CM, McCarthy AC, Blood AJ, Samal L, Fisher N, Orav JE, Plutzky J, Block JP, Bates DW, Rozenblum R, Tucci M, McPartlin M, Gordon WJ, McManus KD, Morrison-Deutsch C, Scirica BM, and Baer HJ
Introduction: There is an urgent need for scalable strategies for treating overweight and obesity in clinical settings. PROPS 2.0 (Partnerships for Reducing Overweight and Obesity with Patient-Centered Strategies 2.0) aims to adapt and implement the combined intervention from the PROPS Study at scale, in a diverse cross-section of patients and providers., Methods and Analysis: We are implementing PROPS 2.0 across a variety of clinics at Brigham and Women's Hospital, targeting enrolment of 5000 patients. Providers can refer patients or patients can self-refer. Eligible patients must be ≥20 years old and have a body mass index (BMI) of ≥30 kg/m 2 or a BMI of 25-29.9 kg/m 2 plus another cardiovascular risk factor or obesity-related condition. After enrolment, patients register for the RestoreHealth online programme/app (HealthFleet Inc.) and participate for 12 months. Patients can engage with the programme and receive personalized feedback from a coach. Patient navigators help to enrol patients, enter updates in the electronic health record, and refer patients to additional resources. The RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework is guiding the evaluation., Ethics and Dissemination: The Mass General Brigham Human Research Committee approved this protocol. An implementation guide will be created and disseminated, to help other sites adopt the intervention in the future., Trial Registration Number: NCT0555925., Competing Interests: Competing interests: HealthFleet Inc. has provided in-kind support for the RestoreHealth programme, but will not be involved in the analysis of the data. AJB reports research grants from Novo Nordisk, General Electric Health and Boehringer Ingelheim. He receives consulting fees from Walgreens Health, Color Health and Arsenal Capital Partners. He has equity in Knownwell. CMA has participated on advisory boards for Altimmune, Cowen and Company, Currax Pharmaceuticals, EPG Communication Holdings, Form Health, Gelesis, Srl., L-Nutra, NeuroBo Pharmaceuticals, Novo Nordisk, Pain Script, Pursuit By You, ReShape Lifesciences, Riverview School and Xeno Biosciences. CMA has received research funding from the NIH, PCORI and GI Dynamics. JP reports research grants from Boehringer Ingelheim, and Novo Nordisk, consulting fees from Altimmune, Amgen, Esperion, Merck, Novo Nordisk and MJH Health. RR reports having equity in Hospitech Respiration, TRI-O, AEYE Health, RxE2, OtheReality, Co-Patient Support and Medyx.ai, all of which are unrelated to this project. He is also receiving research funding from Boston Scientific Corporation, Telem, Calosense Health, Breath of Health, Merative and BriefCam; these are unrelated to this project. WJG discloses consulting income from Novocardia, and Great Point Ventures, both unrelated to this topic. BMS reports institutional research grants to Brigham and Women’s Hospital from Better Therapeutics, Boehringer Ingelheim, Merck, NovoNordisk and Pfizer. Consulting fees from Abbvie (DSMB), AstraZeneca (DSMB), Boehringer Ingelheim, Better Therapeutics, Bristol Myers-Squibb, Elsevier Practice Update Cardiology, Esperion, Hanmi (DSMB), Lexeo (DSMB), Lexicon, NovoNordisk, and equity in Health (at) Scale and Doximity. DWB reports grants and personal fees from EarlySense, personal fees from CDI Negev, equity from ValeraHealth, equity from Clew, equity from MDClone, personal fees and equity from AESOP, personal fees and equity from FeelBetter, personal fees and equity from Guided Clinical Solutions, and grants from IBM Watson Health, outside this project., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)